RS20050930A - Supstituisani spirobenzazepini - Google Patents

Supstituisani spirobenzazepini

Info

Publication number
RS20050930A
RS20050930A YUP-2005/0930A YUP20050930A RS20050930A RS 20050930 A RS20050930 A RS 20050930A YU P20050930 A YUP20050930 A YU P20050930A RS 20050930 A RS20050930 A RS 20050930A
Authority
RS
Serbia
Prior art keywords
compound
chloro
ene
benzoundec
aza
Prior art date
Application number
YUP-2005/0930A
Other languages
English (en)
Serbian (sr)
Inventor
Mona Patel
Phillip Rybczynski
Min Amy Xiang
Original Assignee
Janssen Pharmaceutica N.V.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V., filed Critical Janssen Pharmaceutica N.V.,
Publication of RS20050930A publication Critical patent/RS20050930A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
YUP-2005/0930A 2003-06-17 2004-06-16 Supstituisani spirobenzazepini RS20050930A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47937803P 2003-06-17 2003-06-17
PCT/US2004/019460 WO2005037795A2 (en) 2003-06-17 2004-06-16 Substituted spirobenzazepines

Publications (1)

Publication Number Publication Date
RS20050930A true RS20050930A (sr) 2008-04-04

Family

ID=34465052

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0930A RS20050930A (sr) 2003-06-17 2004-06-16 Supstituisani spirobenzazepini

Country Status (30)

Country Link
US (2) US20040266752A1 (enExample)
EP (1) EP1633719B1 (enExample)
JP (1) JP5252614B2 (enExample)
KR (1) KR101086246B1 (enExample)
CN (1) CN100467454C (enExample)
AR (1) AR044782A1 (enExample)
AT (1) ATE444953T1 (enExample)
AU (1) AU2004281257C1 (enExample)
BR (1) BRPI0411598A (enExample)
CA (1) CA2529649C (enExample)
CL (1) CL2004001507A1 (enExample)
CR (1) CR8168A (enExample)
CY (1) CY1109585T1 (enExample)
DE (1) DE602004023501D1 (enExample)
DK (1) DK1633719T3 (enExample)
EA (1) EA011089B1 (enExample)
ES (1) ES2332724T3 (enExample)
HR (2) HRP20090606T1 (enExample)
IL (1) IL172630A (enExample)
ME (1) ME00320B (enExample)
NO (1) NO20060247L (enExample)
NZ (1) NZ544180A (enExample)
PL (1) PL1633719T3 (enExample)
PT (1) PT1633719E (enExample)
RS (1) RS20050930A (enExample)
SI (1) SI1633719T1 (enExample)
TW (1) TWI354555B (enExample)
UA (1) UA82236C2 (enExample)
WO (1) WO2005037795A2 (enExample)
ZA (1) ZA200600430B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1835926A (zh) * 2003-06-17 2006-09-20 詹森药业有限公司 非肽类取代螺苯并氮杂䓬衍生物的制备方法
EP1984342A2 (en) * 2006-01-20 2008-10-29 Janssen Pharmaceutica, N.V. Novel solid forms of (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid
CA2665851A1 (en) * 2006-09-22 2008-03-27 Janssen Pharmaceutica N.V. Spiro benzazepines as vasopressin antagonists
EP2078022B1 (en) 2006-09-22 2011-11-09 Janssen Pharmaceutica N.V. Spiro benzazepines used as vasopressin antagonists
AR066834A1 (es) * 2007-06-06 2009-09-16 Janssen Pharmaceutica Nv Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central.
CA2705097A1 (en) * 2007-11-07 2009-05-14 Janssen Pharmaceutica N.V. Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
WO2014062888A1 (en) 2012-10-18 2014-04-24 University Of South Florida Compositions and methods for treating stroke
DK2940008T3 (en) 2012-12-26 2017-08-07 Sanwa Kagaku Kenkyusho Co New benzazepine derivative and its pharmaceutical use
CN115427048A (zh) * 2021-03-05 2022-12-02 上海济煜医药科技有限公司 新型苯并氮杂卓并环衍生物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) * 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5985869A (en) * 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
EP0450097B1 (en) 1989-10-20 1996-04-24 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
AU5292393A (en) * 1992-10-07 1994-04-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
ATE312609T1 (de) * 1994-04-22 2005-12-15 Pentech Pharmaceuticals Inc Sublinguale zusammensetzung enthaltend apomorphine zur diagnose der funktionellen impotenz
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JP3282494B2 (ja) * 1995-05-16 2002-05-13 富士ゼロックス株式会社 画像定着装置
US5753715A (en) * 1995-06-02 1998-05-19 Ortho Pharmaceutical Corporation 2-disubstituted cyclohexenyl and cyclohexyl antimicrobial agents
US5726723A (en) * 1996-01-31 1998-03-10 Technology Research International Corporation Sub-twisted nematic liquid crystal display
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
HUP0301590A3 (en) * 2000-07-05 2005-01-28 Ortho Mcneil Pharm Inc Nonpeptide substituted spirobenzoazepines as vasopressin antagonists, pharmaceutical compositions containing them and their preparation
CN1835926A (zh) * 2003-06-17 2006-09-20 詹森药业有限公司 非肽类取代螺苯并氮杂䓬衍生物的制备方法

Also Published As

Publication number Publication date
ME00320B (me) 2011-05-10
HRP20051006A2 (en) 2006-05-31
JP2007521272A (ja) 2007-08-02
KR20060023157A (ko) 2006-03-13
SI1633719T1 (sl) 2010-01-29
EP1633719B1 (en) 2009-10-07
DK1633719T3 (da) 2010-01-04
CR8168A (es) 2008-09-10
EA200501831A1 (ru) 2006-06-30
PT1633719E (pt) 2009-11-11
AU2004281257C1 (en) 2010-07-01
EP1633719A2 (en) 2006-03-15
CY1109585T1 (el) 2014-08-13
KR101086246B1 (ko) 2011-11-23
ZA200600430B (en) 2009-08-26
CN1835925A (zh) 2006-09-20
IL172630A (en) 2011-10-31
CA2529649C (en) 2012-01-31
CL2004001507A1 (es) 2005-05-27
AR044782A1 (es) 2005-10-05
AU2004281257B2 (en) 2010-02-04
HRP20090606T1 (hr) 2010-01-31
CN100467454C (zh) 2009-03-11
US20040266752A1 (en) 2004-12-30
UA82236C2 (en) 2008-03-25
BRPI0411598A (pt) 2006-08-29
US20070179128A1 (en) 2007-08-02
ATE444953T1 (de) 2009-10-15
DE602004023501D1 (de) 2009-11-19
TW200515911A (en) 2005-05-16
US7687494B2 (en) 2010-03-30
NO20060247L (no) 2006-03-13
NZ544180A (en) 2009-01-31
TWI354555B (en) 2011-12-21
WO2005037795A2 (en) 2005-04-28
CA2529649A1 (en) 2005-04-28
EA011089B1 (ru) 2008-12-30
AU2004281257A1 (en) 2005-04-28
JP5252614B2 (ja) 2013-07-31
PL1633719T3 (pl) 2010-03-31
IL172630A0 (en) 2006-04-10
WO2005037795A3 (en) 2005-07-28
ES2332724T3 (es) 2010-02-11
MEP49108A (en) 2011-02-10

Similar Documents

Publication Publication Date Title
US7687494B2 (en) Substituted spirobenzazepines
ES2224604T3 (es) Bococñp(2.2. 1)heptanos y compuestos relacionados.
US7825111B2 (en) Substituted spiroheterocycles
US7285563B2 (en) Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain
AU716122B2 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders
JP2003534343A (ja) 療法において有用なトロパン誘導体
JP2001302631A (ja) バソプレシンおよび／またはオキシトシンレセプタリガンドとしての３−スピロ−インドリン−２−オン誘導体
SK148898A3 (en) Aryl substituted cyclic amines as selective dopamine d3 ligands
TW200815387A (en) Chromen-2-one derivatives
JP2008509115A (ja) スルホンアミド誘導体、この調製およびこの治療用途
JP2010504351A (ja) バソプレッシン拮抗薬として使用されるスピロベンズアゼピン類
KR20160045797A (ko) 리소포스파티드산 수용체 길항제로서의 아미드 유도체
DK2890684T3 (en) URINARY COMPOUNDS AND THEIR USE AS ENZYMINE INHIBITORS
KR20060021373A (ko) 신규 아제티딘 화합물
CN1449386B (zh) 作为血管升压素拮抗剂的非肽取代的螺苯并氮杂*
JP2008546768A (ja) 胃腸疾患を治療するためのニューロキニン受容体アンタゴニストとしての新規なアゼチジン誘導体
ES2247107T3 (es) Nuevos indanilimidazoles policiclicos con actividad adrenergica.
TW200831481A (en) Derivatives of 5-alkyloxy-indolin-2-one, their preparation and their applications in therapeutics
MXPA05014057A (en) Substituted spirobenzazepines
JP3727791B2 (ja) 二環式［３．１．０］ヘキサン及び関連化合物
CN100551915C (zh) 8-氯-2,3-苯二氮䓬衍生物
CA2151243A1 (en) Novel triazolopyrimidones, their preparation and use